
Phase 3 trial shows Johnson & Johnson's dual-target myeloma therapy cuts progression risk by 89%.
Johnson & Johnson announced positive Phase 3 MonumenTAL-6 trial results for its dual antigen therapy TECVAYLI + TALVEY in relapsed/refractory multiple myeloma patients. The combination significantly improved progression-free and overall survival, red...

